Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 24883262)


Immunopathogenesis Versus Protection in Dengue Virus Infections.

Rothman AL, Medin CL, Friberg H, Currier JR.

Curr Trop Med Rep. 2014 Mar 1;1(1):13-20.


Sculpting humoral immunity through dengue vaccination to enhance protective immunity.

Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ.

Front Immunol. 2012 Nov 8;3:334. doi: 10.3389/fimmu.2012.00334. eCollection 2012.


Dengue virus vaccine development.

Yauch LE, Shresta S.

Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Review.


DHIM supporting immunologic investigations and the identification of immune correlates of protection.

Rothman AL.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S61-5. doi: 10.1093/infdis/jiu111.


Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44. doi: 10.1073/pnas.1317350111. Epub 2014 Jan 2. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115.


Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Crill WD, Hughes HR, Delorey MJ, Chang GJ.

PLoS One. 2009;4(4):e4991. doi: 10.1371/journal.pone.0004991. Epub 2009 Apr 1.


T-cell immunity to infection with dengue virus in humans.

Weiskopf D, Sette A.

Front Immunol. 2014 Mar 7;5:93. doi: 10.3389/fimmu.2014.00093. eCollection 2014. Review.


Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.

Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J.

J Virol. 2014 Apr;88(8):4180-94. doi: 10.1128/JVI.03114-13. Epub 2014 Jan 29.


Immune response to dengue virus and prospects for a vaccine.

Murphy BR, Whitehead SS.

Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Review.


The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.


Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.

Tang WW, Grewal R, Shresta S.

Curr Opin Virol. 2015 May 19;13:61-66. doi: 10.1016/j.coviro.2015.04.007. [Epub ahead of print] Review.


Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.

Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS.

PLoS Negl Trop Dis. 2012;6(2):e1486. doi: 10.1371/journal.pntd.0001486. Epub 2012 Feb 28.


Understanding the contribution of cellular immunity to dengue disease pathogenesis.

Mathew A, Rothman AL.

Immunol Rev. 2008 Oct;225:300-13. doi: 10.1111/j.1600-065X.2008.00678.x. Review.


Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Zompi S, Santich BH, Beatty PR, Harris E.

J Immunol. 2012 Jan 1;188(1):404-16. doi: 10.4049/jimmunol.1102124. Epub 2011 Nov 30.


Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity.

Schmid MA, Diamond MS, Harris E.

Front Immunol. 2014 Dec 17;5:647. doi: 10.3389/fimmu.2014.00647. eCollection 2014. Review.


Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.

Briggs CM, Smith KM, Piper A, Huitt E, Spears CJ, Quiles M, Ribeiro M, Thomas ME, Brown DT, Hernandez R.

J Virol. 2014 Jun;88(12):6729-42. doi: 10.1128/JVI.00541-14. Epub 2014 Apr 2.


Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses.

Malavige GN, McGowan S, Atukorale V, Salimi M, Peelawatta M, Fernando N, Jayaratne SD, Ogg G.

Clin Exp Immunol. 2012 May;168(2):215-23. doi: 10.1111/j.1365-2249.2012.04566.x.


An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.

Khanam S, Pilankatta R, Khanna N, Swaminathan S.

Vaccine. 2009 Oct 9;27(43):6011-21. doi: 10.1016/j.vaccine.2009.07.073. Epub 2009 Aug 7.


Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.

Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E.

PLoS Negl Trop Dis. 2012;6(3):e1568. doi: 10.1371/journal.pntd.0001568. Epub 2012 Mar 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk